Understanding Retatrutide: How This Triple Hormone Therapy Works

Looking for weight loss treatment options? Talk with a DevotedDOc healthcare provider.

Retatrutide has gained attention as researchers continue studying new approaches to medical weight management. Unlike medications that target only one or two hormone receptors, retatrutide activates three pathways involved in appetite, blood sugar regulation, and energy balance.

This investigational medication is being developed as a once-weekly injection for adults with obesity, type 2 diabetes, and certain weight-related health conditions. Early clinical trials have reported substantial reductions in body weight, but retatrutide is still undergoing Phase 3 research and has not received FDA approval.

Understanding how retatrutide works can help explain why researchers describe it as a potential next step beyond current GLP-1 medications. However, its long-term effectiveness, safety, and appropriate use still require further study before healthcare providers can prescribe it to the public.

People interested in currently available treatment may explore physician-led weight loss care while researchers continue evaluating retatrutide.

What Is Retatrutide?

Retatrutide is an investigational medication that activates three hormone receptors:

• Glucose-dependent insulinotropic polypeptide, or GIP
• Glucagon-like peptide-1, or GLP-1
• Glucagon

Because one molecule targets all three receptors, researchers classify retatrutide as a triple hormone receptor agonist. It is sometimes informally called a “GLP-3,” but that term is scientifically inaccurate. Retatrutide does not represent a third type of GLP hormone. A more accurate description is a triple agonist because it acts on GLP-1, GIP, and glucagon receptors at the same time.

In clinical trials, participants receive retatrutide as a subcutaneous injection once per week. Its approximately six-day half-life supports weekly dosing, although the medication, dose schedule, and long-term treatment approach remain under investigation.

Eli Lilly is currently studying retatrutide for several conditions, including obesity, overweight with related health complications, type 2 diabetes, obstructive sleep apnea, cardiovascular and kidney outcomes, knee osteoarthritis pain, chronic low back pain, and metabolic dysfunction-associated steatotic liver disease.

Retatrutide is not available through pharmacies, telehealth platforms, compounding pharmacies, or routine medical practices. It is legally available only to participants enrolled in authorized clinical trials. Products marketed online as retatrutide may contain incorrect amounts, unknown ingredients, or harmful contaminants.

How Does Retatrutide Work?

To understand how retatrutide works for weight loss, it helps to look at the role of each hormone receptor separately.

GLP-1, GIP, and glucagon influence different parts of metabolism. By activating all three pathways in a single medication, retatrutide may affect appetite, food intake, insulin response, blood glucose, fat metabolism, and energy use.

Researchers believe this combined mechanism may produce broader metabolic effects than medications that activate only GLP-1 or both GLP-1 and GIP. However, clinical studies are still determining how much each receptor contributes to weight reduction and whether the triple mechanism provides meaningful long-term advantages.

GLP-1 Receptor Activity

GLP-1 is a hormone released from the digestive system after eating. It helps stimulate insulin release when blood glucose rises, reduces glucagon secretion, slows stomach emptying, and sends fullness signals to the brain.

By activating GLP-1 receptors, retatrutide may help people feel satisfied sooner and reduce the amount of food they eat. Slower gastric emptying may also extend feelings of fullness after meals.

These effects resemble those of existing GLP-1 medications. They may also help explain why gastrointestinal symptoms such as nausea, diarrhea, vomiting, and constipation appeared among the most frequently reported adverse events in clinical trials.

Anyone considering an approved GLP-1 medication should discuss potential benefits and common GLP-1 side effects with a qualified healthcare provider.

GIP Receptor Activity

GIP is another hormone released after food intake. It supports insulin secretion and works alongside GLP-1 to help regulate blood glucose after meals.

Retatrutide activates GIP receptors more strongly than its GLP-1 and glucagon targets. Researchers are studying whether this activity may improve insulin response, appetite regulation, and the body’s ability to manage nutrients.

GIP activity is also part of tirzepatide’s mechanism. Tirzepatide, the active ingredient in Zepbound and Mounjaro, targets both GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activation as a third pathway.

Readers exploring medications already approved for weight management can review how Zepbound and Wegovy compare for weight loss. That comparison helps show how current single- and dual-pathway treatments differ from investigational triple hormone therapy.

Glucagon Receptor Activity

Glucagon helps the body maintain blood glucose by signaling the liver to release stored glucose when needed. It may also influence fat metabolism, energy expenditure, and how the body uses nutrients.

Adding glucagon receptor activity is one of the main features that separates retatrutide from currently approved GLP-1 and dual GIP/GLP-1 medications. Researchers believe this third pathway may support increased energy use and changes in fat metabolism while GLP-1 and GIP help manage appetite and glucose regulation.

Glucagon can raise blood glucose under some circumstances, so researchers designed retatrutide to combine its potential metabolic effects with the insulin-supporting activity of GLP-1 and GIP. The goal is to create a coordinated response rather than relying on glucagon activity alone.

Researchers are still studying the exact contribution of glucagon receptor activation. Current evidence suggests that retatrutide’s three-part mechanism may reduce food intake, delay gastric emptying, improve glucose-related measures, and promote weight reduction. Phase 3 studies will help confirm its long-term clinical role.

What Have Clinical Trials Found About Retatrutide Weight Loss?

Although retatrutide is not yet approved for clinical use, early results have generated significant interest among obesity researchers. Early studies suggest that retatrutide may produce greater weight loss than some currently available incretin-based therapies. However, researchers observed these findings under carefully monitored clinical trial conditions.

The largest published Phase 2 trial enrolled adults with obesity or overweight and at least one weight-related condition. Participants received once-weekly retatrutide injections at different doses for 48 weeks while also participating in lifestyle counseling that included healthy eating and physical activity.

Researchers found that weight loss generally increased as the dose increased. At the highest dose studied:

• Average body weight decreased by approximately 24.2% after 48 weeks.
• Nearly all participants lost at least 5% of their starting weight.
• More than 90% lost at least 10% of their body weight.
• More than 80% achieved weight loss of 15% or greater.

The study also reported improvements in several cardiometabolic measures, including blood pressure, blood glucose, waist circumference, and lipid levels. Among participants who had prediabetes at the beginning of the trial, many returned to normal blood glucose levels during treatment.

What Side Effects Have Researchers Reported?

Like other incretin-based medications, retatrutide most commonly caused gastrointestinal side effects. Clinical trials reported nausea, diarrhea, vomiting, and constipation most frequently, especially during dose escalation. Most of these side effects were mild to moderate and became less common after the body adjusted to treatment.

Researchers also observed:

• Temporary increases in heart rate
• Occasional elevations in certain liver enzymes
• Rare cases of pancreatitis and other serious adverse events
• Mild changes in skin sensation in some participants

Because retatrutide remains investigational, researchers continue to evaluate its long-term safety through ongoing Phase 3 clinical trials.

Who May Benefit From Retatrutide?

Researchers are studying retatrutide in adults with obesity or overweight who have weight-related health conditions, as well as in adults with type 2 diabetes. Ongoing Phase 3 studies are also evaluating its potential role in people with cardiovascular disease, obstructive sleep apnea, knee osteoarthritis pain, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic low back pain.

At this time, healthcare providers cannot prescribe retatrutide outside approved clinical trials because it has not received FDA approval. People interested in medical weight management can still discuss currently approved treatment options with a qualified healthcare provider.

For individuals who qualify, getting GLP-1 medications through telehealth may provide access to FDA-approved weight loss medications while investigational therapies such as retatrutide continue through the clinical trial process.

Is Retatrutide FDA Approved?

No. Retatrutide is not FDA approved and remains an investigational medication. It is currently being evaluated in Phase 3 clinical trials to determine its long-term safety and effectiveness before it can be reviewed by the U.S. Food and Drug Administration (FDA).

According to Eli Lilly, retatrutide is being studied across multiple clinical trial programs involving adults with obesity, overweight and weight-related conditions, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, knee osteoarthritis pain, chronic low back pain, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). These studies are designed to determine whether the medication is safe and effective for a variety of metabolic and obesity-related conditions.

Although early clinical trial results have been promising, the FDA must review the complete body of evidence before deciding whether retatrutide should become available for routine clinical use.

Can You Get Retatrutide Right Now?

At this time, the general public cannot legally obtain retatrutide through a prescription, pharmacy, telehealth provider, or commercial weight loss clinic. The medication is available only to eligible participants enrolled in authorized clinical trials.

Because retatrutide has not been approved by the FDA or any other regulatory agency, products marketed online as “retatrutide” should be approached with extreme caution. Eli Lilly warns that products sold outside its authorized clinical trials may contain unknown ingredients, contaminants, incorrect doses, or even different active substances altogether. As a result, these products may pose serious health risks.

For individuals interested in medical weight management today, FDA-approved GLP-1 and GIP/GLP-1 medications remain the appropriate treatment options. A qualified healthcare provider can help determine whether one of these medications is suitable based on your medical history, treatment goals, and overall health.

FAQs

Learn More About Medical Weight Loss

While researchers continue studying retatrutide, several FDA-approved medications are already available to help eligible patients manage obesity and overweight with weight-related health conditions.

At DevotedDOc, our healthcare providers evaluate your medical history, current health, and weight loss goals to determine whether an approved GLP-1 medication may be appropriate for you.

Ready to explore your options? Schedule an appointment with a DevotedDOc healthcare provider to discuss personalized weight loss treatment and learn which evidence-based therapies may be right for you.